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Abstract
Purpose Radium Ra 223 dichloride (radium-223, Xofigo®)
is the first targeted alpha therapy for patients with castration-
resistant prostate cancer and symptomatic bone metastases.
Radium-223 provides a new treatment option for this setting,
but also necessitates a new treatment management approach.
We provide straightforward and practical recommendations
for European nuclear medicine centres to optimize radium-
223 service provision.
Methods An independent research consultancy agency ob-
served radium-223 procedures and conducted interviews with
all key staff members involved in radium-223 treatment deliv-
ery in 11 nuclear medicine centres across six countries
(Germany, Italy, the Netherlands, Spain, Switzerland and the
UK) experienced in administering radium-223. The findings
were collated and discussed at a meeting of experts from these
centres, during which key consensus recommendations were
defined.
Results The recommendations cover centre organization and
preparation; patient referral; radium-223 ordering, preparation
and disposal; radium-223 treatment delivery/administration;
and patient experience. Guidance includes structured coordi-
nation and communication within centres and multidisciplin-
ary teams, focusing on sharing best practice to provide high-
quality, patient-centred care throughout the treatment
pathway.
Conclusions These expert recommendations are intended to
complement existing management guidelines. Sharing best
practice and experience will help nuclear medicine centres to
optimize radium-223 service provision and improve patient
care.
Keywords Bonemetastases . Castration-resistant prostate
cancer . Nuclear medicine . Radium dichloride . Ra-223 .
Targeted alpha therapy
Introduction
Radium Ra 223 dichloride (radium-223, Xofigo®; Bayer AG,
Germany) is a targeted alpha therapy approved for the treat-
ment of castration-resistant prostate cancer (CRPC) with
symptomatic skeletal metastases and no known visceral met-
astatic disease [1–3]. Targeted alpha therapy delivers alpha
radiation to cancer cells and to the tumour microenvironment
while minimizing toxicity to surrounding tissues (Fig. 1)
[4–6]. Radium-223 acts as a calciummimetic, binding to areas
of increased bone turnover in skeletal metastases, subsequent-
ly inducing apoptotic effects through double-stranded DNA
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breaks [6, 7]. The short range of alpha particles emitted by
radium-223 (∼100 μm, or ≤10 cell diameters) mitigates ad-
verse effects on surrounding normal tissue [8]. Furthermore,
radium-223 has a higher linear energy transfer than beta-
emitting radionuclides, leading to more-targeted effects [8].
In the Phase 3 ALSYMPCA study among patients with
CRPC and symptomatic bone metastases, radium-223 signif-
icantly improved overall survival (primary endpoint) and me-
dian time to first symptomatic skeletal-related event (both
p < 0.001; Table 1), compared with placebo, and had a
favourable safety profile [3]. An international early access
Phase 3b study has provided further evidence of the
radium-223 survival benefit in a cohort of patients with
CRPC and bone metastases, who were considered representa-
tive of the typical metastatic CRPC population (Table 1) [9].
Radium-223 was introduced into clinical practice in 2013,
and its benefits and recommendations for use are included in
all major European and US treatment guidelines for CRPC
[10–13]. The approved dose regimen of radium-223 is an
activity of 55 kBq per kg body weight administered by six
intravenous (IV) injections at 4-weekly intervals [1, 2].
Radium-223 is the first available targeted alpha therapy to
significantly extend survival in CRPC. As such, its use in
clinical practice is increasing. However, when offering
radium-223 treatment, a new approach to service provision
is necessary, owing to certain logistic and safety procedures.
Furthermore, building collaboration between the different pro-
fessional teams involved in managing patients with CRPC
will require active input from nuclear medicine, as the main
provider of radium-223.
We report the findings of a project to define expert recom-
mendations from experienced European nuclear medicine
centres to optimize the existing radium-223 service provision
and guide new centres in establishing a radium-223 service.
The focus is on practical aspects of radium-223 service deliv-
ery. Discussion of treatment sequencing with respect to other
agents (e.g., enzalutamide or abiraterone) lies outside the
scope of these recommendations.
Material and methods
Eleven nuclear medicine experts from European centres
across six countries (Germany, Italy, the Netherlands, Spain,
Switzerland and the UK) experienced in using radium-223
were involved in a three-stage project to develop consensus
recommendations. The initial stage involved several days of
onsite observations of radium-223 procedures and patient
treatment pathways in real-life clinical practice at each expert
centre. This was carried out by an independent research
consultancy agency (Alcimed, Paris, France). As part of this
process, interviews were carried out with all key staff
members, including nuclear medicine physicians, nurses,
nuclear medicine technologists/radiographers, oncologists,
radiopharmacists and physicists. The second stage involved
debriefing workshops held in each expert centre with all key
staff members. Best practices that had been observed both in
general processes and in individual stages of the radium-223
patient treatment pathway (e.g., radium-223 injection) were
evaluated. The workshops facilitated alignment between the
staff members on best practice recommendations for that
centre. The third stage was an expert meeting involving all
authors of this manuscript to evaluate the findings and agree
on the recommendations. The best practices identified from
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stages one and two were collated, evaluated and ranked
by importance to identify key consensus best practice
recommendations.
Results
Consensus recommendations to optimize clinical practices
throughout the radium-223 treatment pathway (Fig. 2) are
described below, and the key points are summarized in
Table 2. Guidance was grouped into five categories: centre
organization and preparation; patient referral; radium-223 or-
dering, preparation and disposal; radium-223 treatment
delivery/administration; and patient experience.
Centre organization and preparation
Structured coordination
In most centres, the nuclear medicine physician is responsible
for the therapy service provided for patients and referring
physicians. The aim is to designate a key staff member to be
the main radium-223 service coordinator to oversee the com-
plete treatment pathway. This staff member will communicate
with patients, referring physicians, nuclear medicine physi-
cians and other nuclear medicine centre staff members, repre-
sentatives from radiopharmacy (if present at the hospital),
other departments and Bayer, the pharmaceutical company
providing radium-223.
Close alignment of the nuclear medicine, oncology and urol-
ogy services is recommended to facilitate a multidisciplinary
approach to meet the complex needs of patients with prostate
cancer and to ensure appropriate and efficient care for
individuals receiving radium-223 treatment. This close interac-
tion between departments facilitates identification of patients
who are suitable for radium-223 treatment. Furthermore, it al-
lows the evolution and establishment of a robust care pathway,
ensuring prompt recognition of significant clinical changes dur-
ing the 6-month course of therapy. As part of this multidisci-
plinary approach, the roles and responsibilities of the oncologist
and nuclear medicine physician in providing care during the
radium-223 treatment period need to be clarified. For example,
the point of contact for the patient in general and in the event of
a medical (oncological) emergency, both inside and outside of
office hours, needs to be identified. Some centres are well
supported by an acute oncology service (AOS) that provides
24-h advice, support and management for these patients.
Distribution of the main tasks associated with radium-223
treatment among nuclear medicine team members is advised
to improve efficiency and reduce individual workload.
Opportunities for nuclear medicine physicians to delegate
tasks to other team members are encouraged. To ensure ser-
vice continuity, introduction of an established system to pro-
vide cover for absent team members is recommended, partic-
ularly for the main radium-223 service coordinator, with
trained deputies who can perform all necessary tasks. This will
ensure a seamless service delivery, with no treatment delays.
Dedicated days of the week for radium-223 consultations and
treatments are recommended to assist department workflow.
Depending on clinical demand, 1 defined treatment day each
week would be feasible for most centres. However, to main-
tain flexibility for patients, centres may consider offering treat-
ment on at least 2 days per week, where possible.
Availability of specific administrative documents and elec-
tronically available procedures for radium-223, together with
detailed protocols for all radium-223-related processes, will
Table 1 Summary of key
radium-223 efficacy data in
mCRPC
Parameter ALSYMPCA [3] International EAP [9,
14]
Radium-
223
n = 614
Placebo
n = 307
HR
(95% CI)
N = 696
Median overall survival, months 14.9 11.3 0.70*
(0.58–0.83)
16
(95% CI: 13–NE)
Median time to first SSE, months 15.6 9.8 0.66*
(0.52–0.83)
18
(95% CI: 17–NE)
Median time to total ALP progression,
months
7.4 3.8 0.17*
(0.13–0.22)
8
(95% CI: NE–NE)
Median time to PSA progression, months 3.6 3.4 0.64*
(0.54–0.77)
4
(95% CI: 3–4)
*p < 0.001
ALP, alkaline phosphatase; CI, confidence interval; EAP, early access programme; HR, hazard ratio; mCRPC,
metastatic castration-resistant prostate cancer; NE, not estimated; PSA, prostate-specific antigen; SSE, symptom-
atic skeletal event
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facilitate treatment organization. These are typically devel-
oped by the centre, and address specific processes within the
treatment pathway (e.g., radium-223 order forms and patient
care plans that provide an overview of all six injections and
summarize patient records during the treatment course).
Detailed protocols and flow charts can help staff members to
keep up to date with important processes (e.g., radium-223
disposal), and inform staff who provide cover for absent team
members about tasks that they may perform infrequently.
Staff training
The treatment landscape for CRPC is evolving rapidly; there-
fore, it is recommended that nuclear medicine physicians are
familiar with the management of patients with radium-223
and alternative treatment options; additional focused educa-
tionmay be required. In addition, practical onsite training with
respect to preparing and administering radium-223 injections
should be provided for new and existing staff members
(nurses/technologists/scientific staff). For example, mentoring
sessions could be arranged to ensure that new staff members
undertake up to 20 injections under supervision before they
dispense an injection by themselves. Staff rotation is helpful to
ensure that every responsible staff member maintains their
skills by preparing a radium-223 injection at least once every
2 weeks.
Patient referral
Prior to the introduction of a radium-223 therapy service to a
treatment centre, background information about radium-223
should be provided to referring physicians, including a check-
list to identify patients who are suitable for the treatment. This
will facilitate a streamlined and efficient referral pathway that
Outpatients/inpatients
(treated by urologists/oncologists)
Patients suitable for radium-223
•mCRPC with ≥2 bone metastasesª
•Early symptoms of bone metastases
•Adenopathy ≤3 cm diameter
Patients unsuitable for radium-223
•Presence of visceral metastases 
(lung, liver, brain, diffuse nodal disease)
•Presence of chronic and/or active intestinal
disease (e.g. Crohn’s disease, ulcerative colitis)
•Life expectancy <3 months
NMC Internal oncologistor
•Assess patient
•Assess patient data (scans, blood results)
•Organize missing data
Initial patient consultation
Decision to start radium-223
Blood draw
(internally or externally)
Medical evaluation
(assess patient; assess blood results)
Radium-223 dose ordered
Radium-223 injection
Radium-223 disposal
NMC
Referring oncologist/
urologist
or
Follow-up consultation
After final injection
Patient referral
Six treatment cycles
Fig. 2 Radium-223 treatment
pathway. aDetectable with
99mTc-phosphonate bone scan or
18F-NaF PET/CT scan. CT,
computed tomography; F,
fluoride; mCRPC, metastatic
castration-resistant prostate
cancer; NaF, sodium fluoride;
NMC, nuclear medicine centre;
PET, positron emission
tomography; Tc, technetium
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minimizes any delays because of incomplete information.
This will also ensure that patient expectations are managed,
with appropriate patients who may benefit from radium-223
being referred, and patients who are unsuitable for treatment
being offered alternative strategies.
Regular communication between referring physicians and
the treating nuclear medicine physicians will establish solid
working relationships and keep all parties informed of pa-
tients’ progress. This could be achieved via dedicated com-
munication channels and face-to-face meetings. Such a multi-
faceted approach allows the referring physician to be updated
about patients being treated in the nuclear medicine centre,
and ensures that the nuclear medicine physician is informed
of any general developments regarding the clinical status of
the patient. Strong communication links are also recommend-
ed across the wider multidisciplinary and regional teams, in
whatever format is most appropriate (e.g., regular multidisci-
plinary meetings to discuss individual patient management,
including what to do if a patient becomes unwell during the
treatment course, and regular service provision/audit meetings
at a regional level). Regular multidisciplinary meeting atten-
dance by the nuclear medicine physician (e.g., involving
interdisciplinary experts committed to cancer care – such as
‘tumour boards’ – who discuss and agree upon specific treat-
ment regimens for each patient) is also beneficial. This is
important to reinforce continued awareness among other spe-
cialists about radium-223 as a therapeutic option for patients
with CRPC. Furthermore, both referring physicians and nu-
clear medicine physicians can be informed of any updates or
developments in nuclear medicine and in the prostate cancer
management pathway.
Radium-223 ordering, preparation and disposal
Radium-223 ordering
Many hospitals require dose-specific order numbers to be gen-
erated. To simplify the ordering process, order numbers for all
six radium-223 injections can be created in advance to reduce
administrative workload during the treatment phase. Minor,
unforeseen, intercurrent events may lead to postponement of
radium-223 therapy for a few days. When last-minute cancel-
lations occur and postponement is not possible, it may be
Table 2 Summary of key
recommendations for radium-223
service provision
Category Recommendation
Centre organization and preparation:
structured coordination
Designate a key staff member to be the main radium-223 service
coordinator to interact with everyone involved and oversee
the complete treatment process
Ensure close alignment of the nuclear medicine, oncology and
urology services
Centre organization and preparation: staff
training
Nuclear medicine physicians should be familiar with the
management of patients with radium-223 and alternative
treatment options; additional focused education may be
required
Provide practical training for new and existing staff members
(nurses/technologists/scientific staff) with respect to preparing
and administering radium-223 injections
Patient referral Before the introduction of a radium-223 therapy service, provide
background information about radium-223 for referring
physicians, including a checklist to identify patients who are
suitable for treatment
Radium-223 treatment
delivery/administration: blood tests
Patients should have the option of either two short visits at the
centre (one for blood test, one for injection) or one longer visit
(blood test and injection on the same day)
Alternatively, blood tests may be performed at the local GP
surgery or local hospital. Provision of results by telephone can
be used as an opportunity to discuss the patient’s health status
Radium-223 treatment
delivery/administration: administration of
radium-223
The nuclear medicine physician should undertake a consultation
with the patient at each injection to help build a trusting
relationship and ensure continuity of care
Patient experience: patient comfort and
satisfaction
Patients should have one key worker throughout the treatment
period
Patient experience: patient information Discrepancies between information derived from different
sources should be avoided wherever possible (e.g., provide a
national unified radium-223 flyer)
GP, general practitioner
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possible to switch orders to another patient of similar weight
to avoid wasting the radium-223 dose.
Radium-223 preparation and disposal
It is recommended that dosage calculations be carried out and
double-checked 1 day before scheduled treatment to allow
efficient preparation of injections and, thus, save time on the
day of treatment. Double-checking is important to ensure that
the correct activity of radium-223 is administered. Ideally,
only start the preparation of radium-223 for injection once
patient attendance is confirmed to avoid unnecessary radiation
exposure to staff members and wasting a radium-223 dose.
After preparing the radium-223 syringe, a short plastic line
filled with saline should be attached to the syringe tip as a
safety precaution. This reduces the contamination risk in case
of spillage.
All radioactive waste needs to be handled by properly
trained staff and in accordance with local institutional regula-
tions, but some countries (e.g., Germany) may require addi-
tional special procedures for the disposal of radium-223. Clear
and visible separation of radium-223 waste helps to minimize
exposure of staff members.
Radium-223 treatment delivery/administration
Initial consultation
In the context of advancing underlying disease, it is important
to start radium-223 treatment as soon as possible. No longer
than 1 week between the referral and initial consultation by the
nuclear medicine physician is recommended. The patient’s
general practitioner (GP) should be notified that their patient
is commencing radium-223 therapy in case any other medical
intervention is required during treatment.
It is recommended that patients receive appointments for
all six injections at treatment initiation. However, enough flex-
ibility is needed for patients to reschedule appointments if they
are unable to attend on a particular date. Notably, the survival
benefit with radium-223 in the ALSYMPCA study was ob-
served with some flexibility in the dosing schedule: the 4-
weekly injections could be administered within a window of
−3 days to +7 days, with a delay of no more than 4 weeks for
recovery from adverse events [3]. Advance scheduling of all
six injections has advantages for treatment centres and pa-
tients alike. Both can plan ahead, and the patient has a sense
of security and can integrate the appointments into his daily
life. Depending on local practice, written patient consent can
also be obtained for all six injections in advance at the initial
consultation.
It is important that patients receive detailed information
about radium-223 from a reliable, well-informed source.
Patients could receive their first detailed information on
radium-223 from the referring physician so that they are not
unduly deterred by information on, for example, side effects
or radiation exposure. To achieve this aim, the referring phy-
sician needs to have previously received appropriate back-
ground information from the nuclear medicine department
(see ‘Patient referral’ section). It is also recommended that
additional background information on radium-223 therapy is
sent to the patient prior to the first nuclear medicine consulta-
tion so that they can read it in advance.
It is helpful if a patient can meet both the nuclear medicine
physician and key worker (i.e., key contact person) during the
same visit (see ‘Patient experience’ section for further details
of the key worker). This allows the key worker to be intro-
duced to the patient as early as possible. Advanced planning
of a structured sequence of topics for discussion ensures that
all necessary information is covered during the initial consul-
tation and sufficient time is dedicated to answering the pa-
tient’s questions.
Blood tests
It is recommended that patients receive reminders of their
blood test appointments to streamline care. For patient conve-
nience, the first blood test can be carried out on the same day
as the initial consultation. This ensures that the blood test
results are available quickly so the first injection can be sched-
uled shortly afterwards. In addition, results of the blood test
may identify the need for, and allow arrangement of, interven-
tions prior to treatment (e.g., blood transfusion for low
haemoglobin level). For subsequent blood tests, patients
should be able to choose either two short visits at the centre
(one for blood test, one for injection) or one longer visit (blood
test and radium-223 injection on the same day). Alternatively,
blood tests may be performed closer to the patient’s home, at
either their GP surgery or local hospital. In these instances, the
nuclear medicine physician may be able to telephone the pa-
tient regarding his blood test results. These calls provide an
opportunity to discuss the patient’s health status and confirm
that administration of the next scheduled dose of radium-223
is still appropriate. This task could also be performed by the
key worker or delegated to a radium-223 team member (e.g.,
experienced nurse or technician).
Administration of radium-223
It is recommended that the nuclear medicine physician under-
takes a consultation with the patient when they attend for each
injection. This helps to build a trusting relationship and
ensures continuity of care. This is particularly important in
centres where nuclear medicine physicians do not perform
the radium-223 administration.When feasible, two staff mem-
bers (not necessarily two doctors) should be present at each
injection to ensure that the radioactive material is handled
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correctly. This approach also allows one staff member to pre-
pare the injection while the other takes care of the patient.
Radium-223 is delivered via an IV line and a three-way tap
with Luer Lock connections. When regulations allow, and
with the patient’s consent, an option is to permit attendance
of relatives at the injection procedure.
Patients should receive written information after each treat-
ment cycle to remind them of the hygiene precautions they
should follow post-injection. Documentation confirming that
the patient has received a radioactive injection and contact
details for the centre should be provided.
Follow-up consultation
It is recommended that, where feasible, patients can choose to
have their final consultation with the nuclear medicine or re-
ferring physician, or both. The optimal arrangement will vary
according to local practice.
Patient experience
Patient comfort and satisfaction
High-quality, patient-centred care is essential to ensure opti-
mal patient outcomes. Patients should be supported by one
key worker when they call or attend the centre throughout
the treatment period to provide continuity. This arrangement
provides patients with a familiar person to answer their ques-
tions and allows them to establish a relationship of trust from
the outset. Often this role is carried out by a nurse or medical–
technical radiological assistant (or related professional), but it
could also be a nuclear medicine physician, the same person
who acts as the main radium-223 service coordinator as de-
scribed above, or another member of the nuclear medicine
centre team. If the usual staff member is unavailable, it is
recommended that patients be informed in advance that some-
one else will take care of them for the next appointment.
A key aim is that all appointments allow sufficient time to
ensure patient comfort. About 60 min is suggested for the
initial consultation to enable all relevant information to be
reviewed and questions to be answered, and to obtain in-
formed consent. However, it is recognized that this is a long
appointment time that may not be feasible in all centres.
Physicians should allow approximately 30 min for subsequent
treatment visits in which the patient’s current health status can
be assessed, the treatment room can be prepared and the in-
jection administered. Allowing plenty of time ensures the pa-
tient does not feel rushed. It is recommended that the same
dedicated treatment rooms are used at each visit so that pa-
tients feel relaxed in a familiar environment and know where
they need to go for subsequent appointments. This can be
particularly advantageous for anxious patients and helps to
reduce the psychological stress associated with hospital
attendances. Time delays should be avoided, and, in the con-
text of patients with bone pain or restrictedmobility, it helps to
limit walking distances within the nuclear medicine centre. If
the premises do not allow short walking distances, the centre
should offer facilities to assist patients (e.g., wheelchair
provision).
Systems may be implemented for patients to provide their
feedback on their perception of the care that they have re-
ceived. Examples include a questionnaire at the end of the
treatment or feedback cards left in the waiting area, which
can be completed informally and anonymously. Completed
feedback cards can also be displayed in the waiting area by
the hospital to demonstrate patient satisfaction and/or note
areas for improvement.
Patient information
Written information and educational materials relating to
radium-223 should be made available for patients and their
carers. These can be given to the patient by the referring phy-
sician at, or prior to, the initial consultation and after individ-
ual treatment injections. These materials provide the patient
with a reliable source of information at home, and may help to
reduce the frequency of telephone calls to the centre.
Examples include basic factsheets about radium-223 treat-
ment or the experience of other patients (e.g., regarding the
treatment, what to expect, etc.). Discrepancies between infor-
mation derived from different sources should be avoided
wherever possible. Several countries have developed a nation-
al unified radium-223 flyer that contains streamlined patient
information and prevents potentially contradictory or confus-
ing information being circulated.
Establishing a dedicated radium-223 telephone hotline al-
lows patients to ask questions about their treatment. During
usual business hours, this number would usually connect to
the key worker in the nuclear medicine centre. An alternative
number for use outside business hours (e.g., the AOS hotline)
is also helpful. This information can be given to patients dur-
ing their initial consultation.
Discussion
Nuclear medicine now plays an increasingly important role in
the management of patients with CRPC. Radium-223 is the
first targeted alpha therapy with antitumour properties and
proven significant survival benefits in men with CRPC and
bone metastases. The establishment of radium-223 therapy
into clinical practice requires active input from nuclear medi-
cine specialists.
Here, we present a consensus view of best practice recom-
mendations for centres that are currently treating patients with
radium-223, and for centres that will soon initiate such
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treatment. It is important to note that differences in local insti-
tutional regulations and legal requirements exist. As a result, it
is unlikely that every centre will be able to implement all
recommendations, and, therefore, our intention has been to
provide a comprehensive list of good practices that centres
can implement, taking into account local regulations. This is
not an exhaustive guide to radium-223 treatment provision
and patient care, but is intended to complement country- or
centre-specific management guidelines.
This work distils the combined knowledge and practical
expertise of radium-223 service provision physicians from
ten centres across six European countries. A robust scientific
procedure was followed to identify key processes and recom-
mendations from each centre and then analyse and validate the
results. Although the recommendations provided here origi-
nate from European centres of excellence, it is likely that they
are applicable to other healthcare systems outside of this geo-
graphical region, when used in combination with local
regulations.
Our involvement in developing these best practice guide-
lines has been beneficial to our own nuclear medicine centres
in improving processes. Sharing the key learnings from this
process may help other nuclear medicine centres to facilitate
the efficient use of radium-223 and improve patient care.
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